Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...
In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...
Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...
These days, the frontier AI labs are all racing to build self-improving models. Some believe it’s the surest route to ...
While there have been many sober warnings about AI and recursive self-improvement, Arianna Huffington argues that it is a ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript May 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.50273 EPS, expectations ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...
Covering more ground faster creates better outcomes only if you know which direction to run. Over the course of my career, ...
Governments currently lack the frameworks, technical expertise, and speed to evaluate and regulate such advanced AI. The ...
Microsoft, meanwhile, is trying to turn the trend towards recursive self-improvement into a sales pitch for enterprise AI. In ...